The Underdog in a Monitized Medical System

The Underdog in a Monetized Medical System
​
The Sinclair Method is a cure stuck in the shadows—a simple, effective, evidence-based approach to healing alcohol use disorder. But in a monetized medical system, it has no champions. No pharmaceutical company is running glossy ad campaigns or lobbying to get it into doctors’ offices. It doesn’t generate billions of dollars in profits or create lifelong customers. Instead, it quietly works, rewiring the brain’s reward system, eliminating cravings, and making itself unnecessary over time. And for this very reason, it remains underfunded, underpromoted, and tragically underused.

When I first began to understand the implications of this, I was infuriated. Globally, alcohol use disorder devastates lives. Millions of deaths each year are linked to alcohol, and the ripple effects of its misuse—through accidents, disease, violence, and more—destroy families, communities, and futures. The cost to healthcare systems worldwide is staggering, with billions spent annually treating the conditions caused by alcohol use: liver disease, cancer, heart conditions, mental health disorders, and countless other secondary issues.

And yet, despite all this, a cheap, generic drug like naltrexone—paired with the science-backed protocol of The Sinclair Method—remains in the shadows. Drugs that do far less good but require perpetual use dominate medicine, while this promising approach to one of the world’s greatest public health crises waits for its moment in the light.

The Evidence: A Cure Hidden in Plain Sight
The Sinclair Method isn’t some untested or fringe idea, it is a readily available FDA approved medicine. Its efficacy is supported by decades of research and clinical studies. Time and time again, studies have shown that taking naltrexone before drinking can dramatically reduce alcohol consumption and cravings over time. People who follow the method as prescribed achieve significant reductions in their drinking, with many regaining control over alcohol completely.
Yet these results remain largely confined to smaller studies, limited populations, and underfunded research initiatives. What’s desperately needed is a large-scale clinical trial to bring The Sinclair Method the attention and credibility it deserves. Such a trial could do more than confirm its efficacy—it could transform the way we approach alcohol use disorder entirely. It could take a cure stuck in the shadows and place it at the forefront of global public health efforts.

A System That Prioritizes Profit Over Prevention
In today’s monetized medical system, prevention and cures are often pushed to the back burner. Treatments that require long-term use and create reliable revenue streams are prioritized. For-profit healthcare systems, insurance companies, and pharmaceutical giants have little incentive to invest in a cure that eliminates itself over time.

This is why we see billions poured into treating the fallout of alcohol use rather than addressing the root cause. Drugs to manage liver disease, medications for anxiety and depression, and even expensive surgeries—all of these treatments profit from the damage alcohol leaves behind. But a cure? A method that would prevent these conditions from developing in the first place? There is no ROI. 

The Sinclair Method is the underdog in this system. It’s cheap, generic, and effective, but it doesn’t align with the financial priorities of our current medical landscape. The infuriating truth is that there is no profit in prevention, no profit in eliminating the problem entirely. And so, we continue to pour billions into the aftermath of alcohol use while ignoring the potential of a treatment that could prevent that devastation altogether.

The Cost of Staying Silent
The stakes couldn’t be higher. Alcohol use disorder isn’t just a personal issue—it’s a global crisis. Lives are lost every day, families are torn apart, and healthcare systems are overwhelmed by the burden of alcohol-related conditions. The economic cost alone is staggering, but the human cost is even greater. Every missed opportunity to broaden the understanding and reach of The Sinclair Method is a tragedy.

When I first understood the implications of this cure—a solution hidden in plain sight—I felt a roaring, visceral anger. How could something so simple, so effective, and so life-changing be stuck in the shadows? How could a medical system that spends billions treating the symptoms of alcohol use disorder ignore a treatment that targets the root cause?

The implications for our future are staggering. Unless something changes, millions more lives will be lost, billions more dollars will be spent, and countless families will continue to suffer. The Sinclair Method has the potential to be a game-changer, not just for individuals, but for entire healthcare systems. And yet, without investment, without advocacy, and without awareness, it will remain underutilized, misunderstood, and tragically overlooked.

Who Will Invest in the Future?
What we need is a vision for the future—a future where prevention is prioritized, where public health isn’t dictated by profitability, and where everyone has access to treatments that work. What we need is investment.

A large-scale clinical trial for The Sinclair Method wouldn’t just confirm what smaller studies have already shown—it would transform the global conversation about alcohol use disorder.  It would bring this life-changing treatment into the spotlight and make it part of mainstream medicine. But who will fund it? Who will take on the responsibility of broadening the impact and understanding of this promising cure? 

The answer isn’t clear, but I will work to find a way, silence is no longer an option. We can no longer sit by while millions suffer from a preventable condition. We can no longer allow a monetized system to dictate who gets access to hope and healing.
The Sinclair Method deserves more. People deserve more. And I, for one, could not stay silent. 

UP NEXT, 

THE UNDERDOG IN A MONITIZED HEALTHCARE SYSTEM